Pharmacokinetics, safety profile, and efficacy of Aliskiren in pediatric patients with hypertension

Clinical Pediatrics

Volumn 52, Issue 7, 2013, Pages 599-607

  Sullivan, Janice E ^a   Keefe, Deborah ^b   Zhou, Yinong ^b   Satlin, Lisa ^b   Fang, Hui ^b   Yan, Jing He ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; blood pressure; pediatric hypertension; pharmacokinetics

Indexed keywords

ALISKIREN;

ADOLESCENT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HUMAN; HYPERTENSION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PHARYNGITIS; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; STEADY STATE; SWINE INFLUENZA; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ALISKIREN; BLOOD PRESSURE; PEDIATRIC HYPERTENSION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; AMIDES; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; REGRESSION ANALYSIS; TABLETS; TREATMENT OUTCOME;

EID: 84878892439     PISSN: 00099228     EISSN: 19382707     Source Type: Journal    
DOI: 10.1177/0009922813483875     Document Type: Article

References (19)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 ; 360: 1903-1913
2. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002 ; 288: 1728-1732
3. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 ; 114: 555-576
4. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009 ; 27: 1719-1742
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ; 289: 2560-2572
6. Epstein BJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag. 2010 ; 6: 711-722
7. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007 ; 50: 2398-2404
8. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007 ; 1: 264-277
9. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006 ; 62: 690-698
10. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 ; 18: 139-185
11. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000 ; 17: 1278-1283
12. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 ; 15: 3126-3133
13. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 ; 39: E1 - E8
14. Vaidyanathan S, Limoges D, Yeh C, et al. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2005 ; 79: P64
15. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin DH. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006 ; 45: 1125-1134
16. Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008 ; 46: 252-258
17. Hu P, Bartlett M, Karan RS, et al. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. Clin Drug Investig. 2010 ; 30: 221-228
18. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008 ; 47: 515-531
19. Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs. 2010 ; 70: 2011-2049